Lipoic Acid for Progressive Multiple Sclerosis (MS)
The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.
- Multiple Sclerosis
- Eligible Ages
- Between 18 Years and 70 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Diagnosis of progressive MS as defined by the study - Able to give informed consent and to adhere to study procedures. - Expanded Disability Status Scale (EDSS) 3.0 - 6.5: ambulatory for at least 20 meters without rest and use of bilateral aids (canes, crutches, walker) or better.
- A self-reported medical or neurological problem other than MS that is a cause of progressive or fluctuating gait dysfunction - Unable to undergo MRI - Unable to follow directions in English as standardized scales are not all validated in other languages. - Current major disease or disorder other than MS (e.g., cancer, renal disease, end-stage cardiopulmonary disease, post-traumatic stress disorder, etc.) that may interfere with study procedures. Note: Stable abnormal laboratory values of no more than Grade 1 determined to not be of clinical significance to the primary treating physician for that condition may be permitted per local site investigator discretion. - Pregnant or breast-feeding. - Insulin-dependent diabetes or diabetes not controlled on oral diabetes medications. - Scheduled (every 3 months or more frequently) IV or oral steroids in the year prior to enrolment. - IV or oral steroids in the 60 days prior to enrolment. - Use of LA in the prior 2 years exceeding the equivalent of 1200mg daily for 3 months. - Participation in the pilot LA in SPMS trial.
- Phase 2
- Study Type
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm 1: Lipoic Acid
|59 subjects receive oral lipoic acid 1200mg daily||
Arm 2: Placebo
|59 subjects receive placebo daily||
- VA Office of Research and Development
Study ContactLauren Cameron
This two-year study will determine if daily oral intake of lipoic acid will prove superior to placebo in reducing injury to the brain and maintaining mobility in progressive MS. Mobility will be assessed with the timed 25-foot walk test and 2-minute timed walk test as well as fall counts. Neuroprotection will be measured by the extent of brain volume loss seen on MRI.